Literature DB >> 34619766

Typhoid fever in travellers: estimating the risk of acquisition by country.

Daniel P Forster1,2, Karin Leder2,3.   

Abstract

BACKGROUND: Typhoid fever is a notifiable disease within Australia. Although studies in endemic regions give an indication of acquisition risk, many countries lack reliable data, and little is known of the absolute or relative risk in Australian travellers. By combining notified case data with travel statistics provided by the Australian Bureau of Statistics, the aim of this study was to give an indication of risk for typhoid acquisition among Australian travellers.
METHODS: Australian typhoid notifications between 1st January 2010 and 30th June 2017 were grouped by country of acquisition and age category (<15 or ≥15 years). Australian travel data were used to inform time at risk and incidence rate of Australian typhoid notifications pertaining to country and region of acquisition. Salmonella Paratyphi infections, though notifiable, were excluded as the focus was vaccine preventable illness. Data from New South Wales and Victoria were used to examine the incidence in those acquiring infection in their country of birth (COB) against travellers who did not.
RESULTS: Nine hundred twenty-three cases of typhoid were notified over the period of review, 96% of which were acquired overseas. The greatest determinant of risk was travel destination, with countries in south Asia associated with highest crude incidence rate (252 per 100 000 person-years), particularly Bangladesh. Younger age and immigrants returning to their COB were generally associated with higher risk of acquisition.
CONCLUSIONS: The risk of typhoid fever in Australian travellers to endemic regions is considerable. Immigrants returning to their COB appear to be at higher risk and it is likely that this risk extends to their traveling dependents. These findings help clinicians and public health officials to plan and advise pre-travel vaccination strategies with at-risk individuals and groups. Additional sociodemographic data collection with Australian typhoid notifications would enhance the surveillance of differing international travel risk groups leaving Australia.
© The Author(s) 2021. Published by Oxford University Press on behalf of International Society of Travel Medicine.

Entities:  

Keywords:  zzm321990 salmonella typhi; Enteric fever; imported infection; surveillance; travel; vaccine-preventable disease; visiting friends and relatives (VFR)

Mesh:

Substances:

Year:  2021        PMID: 34619766      PMCID: PMC8715417          DOI: 10.1093/jtm/taab150

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


Introduction

Typhoid fever is a systemic illness that causes considerable worldwide morbidity and mortality. Salmonella enterica subspecies enterica serovar Typhi (Salmonella Typhi) is the causative bacterium, transmitted primarily via the faecal oral route and with humans acting as the sole reservoir. Noted to be a disease of poverty, the illness disproportionately affects countries and regions with poor water supply and sanitation with south and southeast Asia, western and eastern sub-Saharan Africa and Oceania identified as regions of highest incidence. Travellers to these regions are at risk of acquiring infection, and in addition to advice to optimize safe food and water practices, may be offered the oral or injectable typhoid vaccine pre-travel. Salmonella enterica subspecies enterica serovar Paratyphi (Salmonella Paratyphi) causes paratyphoid fever which has a similar route of acquisition and clinical presentation to typhoid fever. However, despite limited data suggesting the oral typhoid vaccine may provide cross-protection for Salmonella Paratyphi B (albeit without established effectiveness for either Salmonella Paratyphi A or C),  Salmonella Paratyphi currently has no licensed vaccines available. Diagnosis of typhoid fever is typically made via culturing Salmonella Typhi from blood. The sensitivity of culture is dependent both on the volume of blood collected and prior antibiotic use. Bone marrow sampling for culture may increase diagnostic sensitivity, but this is offset by added resource use, procedural risks and patient discomfort which preclude its routine use in the work-up of suspected cases. In most regions of high typhoid endemicity, underdiagnosis related to low rates of presentation to health care, as well as lack of diagnostic testing facilities, making it difficult to accurately measure the burden of typhoid disease on a global scale. Existing estimates of typhoid fever incidence in higher incidence settings have typically relied on control arms of vaccine trials, population-based or household-level active surveillance, sentinel studies or prospective observational studies. Multipliers are often applied to derive incidence estimates which account for known difficulties in case detection and underdiagnosis., Studies and reviews from low incidence countries, including the USA, UK, Israel, Canada and the Netherlands, have noted predominant overseas acquisition of the disease and sought to estimate risk and/or vaccine efficacy to help guide pre-travel vaccine recommendations. Risk estimates for travellers have typically been recorded as incidence proportions (notifications per 100 000 travellers) rather than incidence rates [notifications per 100 000 person-years (PY)] with a lack of data obtained for travellers to endemic Oceanic countries., Australia, a high-income country, is the largest country both by population size and geographical area in the Oceania region which consists of 14 member countries. Typhoid is a notifiable disease in Australia, with reporting of cases from both the diagnostic laboratory and treating clinician required by law to the National Notifiable Diseases Surveillance System (NNDSS). Confirmed cases are notifiable with diagnostic confirmation dependent on definitive laboratory evidence via culture. Serological testing is not accepted as a confirmatory test and with rare exceptions (most commonly stool culture in the setting of screening known contacts); a positive blood culture is the predominant form of diagnosis. Access to health care and diagnostic testing capability are excellent in Australia, so combined with mandatory notification of confirmed typhoid, case capture is considered high. Notification data confirm that most diagnosed cases are acquired overseas, with overall notification rates consistently <1 per 100 000 PY, well within the definition of a low-incidence country (<10 cases per 100 000 PY). In 2018, an estimated 29% of Australian residents were born overseas. Prior to the COVID-19 pandemic, international travel for tourism or business, or by those returning to their country of birth (COB) to visit friends and relatives (VFR) occurred at a high rate. VFR travellers compared with other travellers have been established as having higher relative risk for several infectious diseases endemic to their country of origin, including typhoid., This is presumed to relate to a range of factors including under-recognition of potential risks from consuming local food and water., Temporary visitors from endemic regions may be another source of typhoid notifications; while unable to be distinguished from routine travellers in case notification data, they are unlikely to be a prominent source of typhoid notifications., Australians frequently travel to high-risk destinations within the Asia-Pacific region, so notification rates and risks may differ from those reported in other studies. Therefore, we have examined Australia’s typhoid notifications, and combined these data with travel statistics kept by the Australian Bureau of Statistics (ABS) to estimate the risk of typhoid following travel to a range of countries to help guide optimal vaccine prevention strategies. The specific aims of this study were to (i) provide a summary of Australian Salmonella Typhi notifications for period of 1st January 2010 to 30th June 2017, (ii) apply denominator travel data to enable the estimation of typhoid fever incidence rates for Australian travellers by age and country of acquisition (COA) and (iii) where possible, examine the relative risk of infection for travellers returning to their COB vs other travellers.

Methods

Notified typhoid fever cases

Case data for the period 1st January 2010–30th June 2017 in 6 monthly time periods were requested from NNDSS, including classification by age (<15 or ≥15 years) and COA. NNDSS co-ordinates the national surveillance of more than 50 communicable diseases, including typhoid. Data collected by State and Territory Health departments are de-identified prior to forwarding to the NNDSS. Reason for travel, residency status and COB are not routinely collected at the national level, so were instead sought from individual state and territory health departments. COB data for notified cases were able to be provided by the two largest Australian state health departments, New South Wales (NSW) and Victoria (VIC), but reason for travel and residency status was not routinely recorded and not obtainable.

Travel data

Travel statistics collected by the ABS include aggregated information on departing travellers from, and incoming travellers to, Australia. A distinction is made between short-term (<12 months travel) and long-term travel (>12 months) and category of traveller—Australian resident (all Australian citizens, permanent visa holders and any New Zealand citizens who can be identified as a resident) or visitor. Until 30th June 2017, all individuals departing Australia were required to complete a departure card which recorded main destination, duration and reason for travel (Appendix S1, Supplementary data are available at JTM online). Collated data on short-term travellers are publicly available, but we requested additional aggregated data from the ABS on departing Australian residents (with <12 months planned travel) grouped by age (<15 or ≥15 years), resident state or territory, main destination country and main reason for travel. Aggregated number of movements and duration of overseas travel (days) were supplied for Australian-born, overseas-born (returning to COB) and overseas-born (not returning to COB) individuals. The Standard Australian Classification of Countries, 2016, was used to classify countries into major and minor world groupings.

Data analysis

Notified typhoid case data were recorded in 6-month time periods against age category of case (<15 or ≥15 years) and COA. ABS outbound travel data included intended travel duration which was used to provide time at risk, enabling calculation of incidence rates for major and minor world group sets and individual countries. Incidence rates (cases per 100 000 PY) were calculated using the formula: x/d × 365.25 × 100 000, where x = number of typhoid notifications and d = total days exposure. Calculations assumed that travellers with multiple destinations spend their entire travel time in the main country visited, that all cases were notified and that notifications were acquired through short-term travel of Australian residents. Population level data were obtained; therefore, risk estimates were calculated without confidence intervals. For notifications from NSW and VIC, the dataset additionally recorded if COB and COA were the same (COB = COA), and incidence rates were additionally calculated according to whether this variable was recorded as ‘Yes’, ‘No’ or ‘Unknown’. ‘Unknown’ results for this variable were imputed in the base case analysis assuming that results were missing at random. To examine the effect of missing data assumptions, a sensitivity analysis was undertaken with all missing data for the dummy variable imputed as ‘Yes’ then ‘No’ to create high and low estimates. Data were received and recorded de-identified in a secure electronic database (excel). Statistical analyses were performed using statistical software (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC).

Results

Over the 7.5 years of this retrospective review, 923 cases of typhoid were notified within Australia, 887 (96%) of which were acquired overseas. Only 36 cases (4%, <5 notifications per year) were acquired locally (from an approximate Australian population of 23 million). Most notifications were attributable to acquisition in south Asia (n = 668, 72%) followed by southeast Asia (n = 94, 10%), and Oceania (n = 75, 8%), with India being the most common COA (n = 496, 54%). Individuals aged ≥15 years (n = 669, 73%) were predominant in notifications. When denominator data were applied, south Asia (252 cases per 100 000 PY) still had the highest crude incidence rates for acquisition, but Bangladesh had the highest rate (584 cases per 100 000 PY), followed by India (282 cases per 100 000 PY), Pakistan (264 cases per 100 000 PY) and Nepal (189 cases per 100 000 PY) (Table 1). Samoa (342 cases per 100 000 PY) in Oceania and Myanmar (101 cases per 100 000 PY) in southeast Asia were also found to be associated with high acquisition risk. Of 10 destination countries with comparative data, seven were found to have incidence rates higher in individuals aged <15 years compared with ≥15 years (Table 1).
Table 1

Incidence of Australian typhoid notifications in Australian travellers—1 January 2010 to 30 June 2017

Typhoid Acquisition World Region Minor Region CountryAustralian notified typhoid cases (n)Travel exposure (days)—returning Australian residents^Travel episodes (n)£Typhoid incidence (per 100 000 PY)—crude estimatesδ
  Age (years)<15≥15Total<15≥15TotalTotal<15≥15Total
OCEANIA 19 56 75 24 180 310 154 700 970 178 881 280 13 336 120 28.7 13.22 15.31
Melanesia1314272 338 45022 422 11024 760 5601 330 140203.0522.8139.83
Papua New Guinea 1314271 112 11013 941 58015 053 690684 540426.9636.6865.51
Micronesia10173 6501 626 2801 699 93083 580495.9321.49
Nauru 10140 7101 084 4801 125 19057 340897.2032.46
Polynesia (excl Hawaii)541467 231 48030 109 40037 340 8802 924 59025.2549.7444.99
Samoa 52934668 8302 959 3703 628 200178 130273.05357.92342.28
Fiji 010105 954 79023 285 33029 240 1202 478 91015.6912.49
Tonga 011264 9601 485 9001 750 86088 35024.5820.86
American Samoa 011870777086404104700.774227.43
New Zealand01114 432 30099 198 980113 631 2808 866 9900.370.32
SOUTH AND CENTRAL ASIA * 203 466 669 21 616 460 79 132 940 100 749 400 2 909 480 343.01 215.09 242.53
Southern Asia20346466721 148 90075 555 11096 704 0102 824 880350.59224.31251.93
India 13136549614 636 84049 619 91064 256 7501 843 930326.90268.67281.94
Bangladesh 3049791 209 7103 728 0004 937 710123 850905.80480.08584.38
Pakistan 4122632 555 0906 175 2608 730 350178 230586.09130.12263.57
Nepal 12425585 5104 257 5104 843 020147 25062.38205.89188.54
Sri Lanka 0442 067 22010 648 65012 715 870449 97013.7211.49
Central Asia011467 5603 577 8304 045 39084 60010.219.03
Afghanistan 011363 5202 406 0802 769 60055 50015.1813.19
SOUTH EAST ASIA * 10 84 94 41 865 140 316 516 140 358 381 280 19 756 840 8.72 9.69 9.58
Mainland SE Asia1161713 411 810117 742 960131 154 7706 366 8102.724.964.73
Cambodia 145906 5208 135 3809 041 900339 30040.2917.9620.20
Myanmar 077230 9102 291 3902 522 30099 110111.58101.37
Thailand 0557 044 99066 714 38073 759 3704 159 4502.742.48
Maritime SE Asia9677628 453 330198 773 180227 226 51013 390 03011.5512.3112.22
Indonesia 6495514 084 33089 352 890103 437 2207 450 13015.5620.0319.42
Philippines 312154 238 97031 936 29036 175 2601 369 26025.8513.7215.15
Singapore 0224 948 02036 710 07041 658 0902 469 2101.991.75
Timor-Leste 022331 5703 249 2003 580 770115 90022.4820.40
Malaysia 0224 728 21036 622 18041 350 3901 954 4901.991.77
NORTH EAST ASIA * 0 2 2 24 712 470 181 363 230 206 075 700 7 237 700 0.40 0.35
Chinese Asia (incl Mongolia)02218 600 930139 855 720158 456 6505 035 3700.520.46
Hong Kong 0113 902 97039 247 73043 150 7001 620 5500.930.85
SUB-SAHARAN AFRICA 3 6 9 4 058 440 31 538 300 35 596 740 1 132 060 27.0 6.95 9.23
Central & W Africa112201 8603 062 8603 264 72074 060180.9411.9322.38
Guinea 1012520135 390137 910538014 494.1264.85
Ghana 01187 550980 0501 067 60022 92037.2734.21
South and East Africa2573 856 58028 475 44032 332 0201 058 00018.946.417.91
Zambia 21387 720742 070829 79020 300832.7649.22132.05
Tanzania 01185 5901 694 9401 780 53051 21021.5520.51
South Africa 0111 967 22015 578 79017 546 010649 0802.342.08
Somalia 01157 720213 300271 0204100171.24134.77
Djibouti 0116026 85026 9104201360.341357.30
NTH AFRICA AND MIDDLE EAST 0 12 12 11 334 600 55 663 150 66 997 750 1 549 120 7.87 6.54
North Africa0331 151 5706 319 3307 470 900176 53017.3414.67
Sudan 033302 7001 061 5301 364 23023 550103.2280.32
Middle East09910 183 03049 343 82059 526 8501 372 5906.665.52
Lebanon 0443 203 36010 568 35013 771 710273 00013.8210.61
Iran 011742 5303 705 9504 448 480102 6709.868.21
Syria 011148 090498 690646 78010 83073.2456.47
Iraq 022873 8002 398 4303 272 23058 56030.4622.32
Saudi Arabia 011450 0502 886 8903 336 94064 00012.6510.95
AMERICAS 0 2 2 20 216 630 208 978 210 229 194 840 8 499 370 0.35 0.32
Central America022323 0705 456 6005 779 670155 21013.3912.64
El Salvador 01145 720393 370439 090851092.8583.18
Mexico 011203 4703 771 8803 975 350117 1309.689.19
SOUTHERN AND EASTERN EUROPE 0 1 1 10 785 160 117 876 480 128 661 640 3 226 650 0.31 0.28
Eastern Europe0111 743 00013 402 96015 145 960366 7302.732.43
Czechia 011277 6801 744 5802 022 26047 95020.9418.06

NNDSS data were provided by the Office of Health Protection, Department of Health, on behalf of the Communicable Diseases Network Australia—2019 August 20.

Additional 23 cases with unknown COA (age < 15 years n = 6, age ≥ 15 n = 17) and 36 cases locally acquired in Australia (age < 15 years n = 13, age ≥ 15 n = 23).

^Based on ABS, Customized Report, 2019.

£Total travel episodes—returning Australian residents <12 months overseas travel.

δCrude incidence estimates under assumption that 100% of typhoid notifications were in returning Australian residents.

*Includes 1 case attributed to region but not specific country.

Incidence of Australian typhoid notifications in Australian travellers—1 January 2010 to 30 June 2017 NNDSS data were provided by the Office of Health Protection, Department of Health, on behalf of the Communicable Diseases Network Australia—2019 August 20. Additional 23 cases with unknown COA (age < 15 years n = 6, age ≥ 15 n = 17) and 36 cases locally acquired in Australia (age < 15 years n = 13, age ≥ 15 n = 23). ^Based on ABS, Customized Report, 2019. £Total travel episodes—returning Australian residents <12 months overseas travel. δCrude incidence estimates under assumption that 100% of typhoid notifications were in returning Australian residents. *Includes 1 case attributed to region but not specific country. COB was available only for notifications from NSW and VIC (n = 615), representing two-thirds of all cases (Appendix S1B, Supplementary data are available at JTM online) and ~62% of total Australian resident travel. NSW/VIC travellers returning to their COB were found to have greater relative risk of acquiring typhoid regardless of destination country (Table 2). Stratification by this variable showed every destination country to have greater relative risk in individuals aged <15 years compared with ≥15 years, including the three countries—Samoa, Nepal and Indonesia—that did not show this age association unstratified (Table 1). Sensitivity analyses showed altered magnitude of relationships but a consistent increase in relative risk for those returning to their COB (Appendix S2, Supplementary data are available at JTM online).
Table 2

Typhoid fever incidence in NSW/VIC travellers acquiring infection in their COB vs not acquiring in COB—1st January 2010–30th June2017

Country of typhoid acquisition and age category (years)Typhoid notifications—n (adjusted)*Travel exposure—daysIncidence—per 100 000 PY^IRR (COB=COA:COB≠COA)
COB=COACOB≠COATotalCOB=COACOB≠COATotalCOB=COACOB≠COATotal
India<1531 (33)53 (57)902 458 3507 314 1309 772 480490.30284.64336.381.72
≥15199 (214)26 (28)24224 009 0509 580 68033 589 730325.56106.75263.153.05
Bangladesh<155 (6)13 (15)21147 540777 310924 8501485.36704.83829.352.11
≥1535 (36)3 (3)392 390 850410 2402 801 090549.97267.10508.542.06
Pakistan<159 (10)17 (18)28471 9201 374 3301 846 250773.97478.38553.931.62
≥1512 (12)4 (4)162 659 5201 619 3704 278 890164.8090.22136.581.83
Nepal<151 (1)0 (0)145 630380 980426 610800.4685.62
≥1514 (14)2 (2)161 099 0501 699 9102 798 960465.2742.97208.7910.83
Indonesia<150 (0)2 (2)2453 8706 463 2606 917 13011.3010.56
≥1513 (14)9 (10)247 343 05035 296 80042 639 85069.6410.3520.566.73
Cambodia<150 (0)1 (1)159 670580 010639 68062.9757.10
≥152 (2)2 (2)41 658 9703 234 1804 893 15044.0322.5929.861.95
Thailand<150 (0)0 (0)0412 8804 033 6304 446 510
≥151 (1)4 (4)53 493 31034 443 34037 936 65010.464.244.812.46
Samoa<150 (0)2 (2)221 950398 230420 180183.44173.85
≥1511 (15)1 (2)17884 680937 0301 821 710619.2977.96340.857.94
Fiji<150 (0)0 (0)098 9204 261 8504 360 770
≥154 (5)3 (0)83 314 77012 657 66015 972 43055.098.6618.296.36

IRR = Incidence rate ratio.

Only countries with at least one available comparison shown

*(Adjusted) includes imputed cases with unknown COB assumed to be missing at random.

^Incidence = notifications (adjusted)/travel exposure × 365.25 × 100 000.

See Appendix S2, Supplementary data are available at JTM online, for extended countries data and sensitivity analysis for effect of missing data assumptions

Typhoid fever incidence in NSW/VIC travellers acquiring infection in their COB vs not acquiring in COB—1st January 2010–30th June2017 IRR = Incidence rate ratio. Only countries with at least one available comparison shown *(Adjusted) includes imputed cases with unknown COB assumed to be missing at random. ^Incidence = notifications (adjusted)/travel exposure × 365.25 × 100 000. See Appendix S2, Supplementary data are available at JTM online, for extended countries data and sensitivity analysis for effect of missing data assumptions

Discussion

We have used notification and travel pattern data to determine the incidence of typhoid notification among Australian travellers. As has been shown previously, we confirm that travel destination is the most important risk factor for typhoid acquisition and that south Asia is associated with the largest number of notifications and highest crude incidence rates. India, Pakistan, Bangladesh and Nepal had rates of infections in travellers broadly consistent with that of a recent systematic review of internal studies from this region, and our findings align with previous reports suggesting that notified typhoid cases in Australia are predominantly acquired in India. Sri Lanka, compared with its neighbouring countries in south Asia, was notable for lowered apparent risk. Although recent published comparative data are sparse, national surveillance and vaccination programs exist within Sri Lanka and our data support the effectiveness of control measures in place. Acquisition of typhoid in southeast Asia appeared to be an order of magnitude lower than south Asia. Frequently travelled countries in this region including Vietnam, Singapore, Malaysia and Laos were associated with very few or no notifications, which is consistent with published literature of lowered endemic rates in these countries., The greatest number of typhoid notifications were associated with travel to Indonesia, but Myanmar (101 cases per 100 000 PY) was associated with the highest regional risk and would meet the definition of a high incidence country at >100 cases per 100 000 PY. While our results are based on only a small number of case notifications, they are broadly comparable to a study from Yangon, Myanmar that combined sentinel hospital surveillance and multipliers derived from a household healthcare utilization survey in determining an estimated incidence of 391 cases per 100 000 PY in 2015/16. Within Oceania, the risk of acquiring typhoid was notable for Samoa (342 cases per 100 000 PY) which was higher than most countries of south Asia. This is potentially an alarming finding and suggests possible under-reporting of cases locally in Samoa. A study that was published recently reported that, based on internal health data, annual incidence rates over the same period ranged between 27.5 cases and 101.9 cases per 100 000 PY in 2014 and 2012, respectively. Data from New Zealand tend to support our findings, indicating prominent acquisition of typhoid associated with travel to Samoa. The calculated incidence for Auckland resident travellers to Samoa between 2005 and 2010 was determined to be 19.7 per 100 000 travellers. Annual reports from New Zealand, where typhoid is also notifiable, indicate that Samoa was either the first or second (after India) most common place of travel-associated infection between 2010 and 2017, with 5–21 case notifications per year. Incidence rates from studies and reviews of Fiji are more comparable to our results (12.5 cases per 100 000 PY), placing Fiji in a moderate range of 10 to <100 cases per 100 000 PY., We found that Papua New Guinea was a prominent place of acquisition (65 cases per 100 000 PY) with a high rate detected particularly in the ≤15 age category. Unfortunately, a paucity of published data exist to compare this finding and most of the notifications in this study were from outside NSW/VIC, making it impossible to investigate the effect of COB on acquisition risk. Nauru, Tonga and American Samoa each had single notifications over the study period, but small populations and relatively little returning travel from Australia mean risk assessments are imprecise. Likewise, small numbers of notifications and relatively little travel limited the assessment of other known endemic regions of the world including Africa and South and Central America. The low case numbers from these areas, particularly from sub-Saharan Africa, are in line with other reports among travellers,,; although not well-understood generally, these findings may be explained in our study by the predominance of South Africa as the exposure country and its presumed lower risk compared with others in the region. Younger age has frequently been associated with higher risk of acquiring typhoid in a variety of study types and locations, as reflected in a recent systematic analysis informing global disease burden. While neonates appear relatively protected through exclusive breastfeeding, the risk rapidly rises with considerable burden in pre-school aged children and peak incidence occurs under the age of 10. Consistent with prior studies, our data showed that most locations had higher incidence rates for age < 15 compared with ≥15 years, with exceptions being Indonesia, Nepal and Samoa. For the subset of NSW/VIC travellers for whom COB data were available, we assumed that those returning to their COB would likely be engaged in VFR travel, a factor that has been previously established as greater risk for acquisition of typhoid., Unfortunately, this was likely a sub-optimal stratification method for age < 15 years, where Australian-born children of immigrant parents (often referred to as second generation VFRs) were unable to be distinguished. A better division would likely be achieved in this age group by categorizing based on their parents’ COB, or ideally on reason for travel, but unfortunately neither of these data was available. Only India, Pakistan and Bangladesh had sufficient attributable notifications in the ≤15 years age group to examine the relative risk of children returning to their COB vs not traveling to their COB, with RRs of 1.72, 1.62 and 2.11, respectively. For age ≥ 15 years, the greater relative risks of travellers returning to their COB were most pronounced for Nepal (RR 10.83), Indonesia (RR 6.73), Samoa (RR 7.94) and Fiji (RR 6.36) and were also seen to a lesser degree for India (RR 3.05), Bangladesh (RR 2.11), Pakistan (RR 1.83), Cambodia (RR 1.95) and Thailand (RR 2.46). Overall, our findings concur with previous studies of travellers from low-incidence countries in identifying south Asia as a prominent region for acquisition of typhoid., Importantly, however, our analysis provides a contemporaneous assessment of the Asia-Pacific region including Oceanic countries that to date have had little data evaluation. The limited ability to assess subcategories of risk, including reason for travel, highlights that such information ideally should be routinely captured in case notification data to help identify and focus preventive strategies on those with greatest need. Our study has several limitations. Firstly, we may have underestimated typhoid acquisition since case ascertainment required diagnosis of typhoid to occur in Australia following return from abroad. We may have also underestimated the absolute risks given some (unknown proportion of) travellers may have received typhoid vaccine prior to travel. However, our data are directly relevant for Australian healthcare utilization estimates. Secondly, data were gained retrospectively and are subject to several limitations. Exposure data were based on aggregated estimates of intended rather than confirmed travel duration. Additionally, travel time was apportioned to the main country of destination and therefore could not account for travel to multiple destinations, potentially resulting in misclassification when assessing results for individual countries. Thirdly, detailed denominator data were obtained only for returning Australian residents with less than 12 months of travel, with exclusion of newly arrived immigrants, those involved in long-term travel and short-term visitors to Australia, the latter being the largest in number. Unfortunately, residency status was not routinely recorded for cases, so it was not possible to examine this. Publicly available short-term visitor data to Australia over the period of this study indicate that short-term visitors account for 8–50% of travel episodes between typhoid endemic countries and Australia, with variation across countries and regions. Finally, the period of 7.5 years for this study was used to allow for greater numbers of notifications for individual countries, to mitigate seasonal effects and to balance the concern that time periods for notifications and travel could not be perfectly aligned. However, this period was insufficient to enable an assessment of risk variability over time for different destinations.

Conclusion

This study of typhoid acquisition in returning Australian travellers gives important information on several factors crucial to understanding disease transmission and risks associated with disease acquisition. Our findings particularly shed light on risks among travellers to destinations within Oceania and will help clinicians to provide informed advice regarding pre-travel typhoid vaccination. Additionally, we have identified areas where capture of enhanced notification information on reason for travel and residency status would be beneficial, ideally extending data collection to the parent(s) of notified traveling dependents. Capturing the vaccination status of cases would also be informative. Such data could be used to provide more precise risk characterization that could underpin future targeted public health strategies. Click here for additional data file. Click here for additional data file.
  33 in total

1.  The global burden of typhoid fever.

Authors:  John A Crump; Stephen P Luby; Eric D Mintz
Journal:  Bull World Health Organ       Date:  2004-05       Impact factor: 9.408

2.  Effectiveness of the typhoid Vi vaccine in overseas travelers from England.

Authors:  Karen S Wagner; Joanne L Freedman; Nick J Andrews; Jane A Jones
Journal:  J Travel Med       Date:  2014-11-30       Impact factor: 8.490

3.  Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B.

Authors:  Myron M Levine; Catterine Ferreccio; Robert E Black; Rosanna Lagos; Oriana San Martin; William C Blackwelder
Journal:  Clin Infect Dis       Date:  2007-07-15       Impact factor: 9.079

4.  Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment.

Authors:  Vittal Mogasale; Brian Maskery; R Leon Ochiai; Jung Seok Lee; Vijayalaxmi V Mogasale; Enusa Ramani; Young Eun Kim; Jin Kyung Park; Thomas F Wierzba
Journal:  Lancet Glob Health       Date:  2014-10       Impact factor: 26.763

5.  East London experience with enteric fever 2007-2012.

Authors:  Jayshree Dave; Michael Millar; Horst Maxeiner; Joanne Freedman; Rachel Meade; Caryn Rosmarin; Matthew Jordan; Nick Andrews; Richard Holliman; Armine Sefton
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

6.  The burden of typhoid fever in low- and middle-income countries: A meta-regression approach.

Authors:  Marina Antillón; Joshua L Warren; Forrest W Crawford; Daniel M Weinberger; Esra Kürüm; Gi Deok Pak; Florian Marks; Virginia E Pitzer
Journal:  PLoS Negl Trop Dis       Date:  2017-02-27

7.  Incidence of Typhoid and Paratyphoid Fevers Among Adolescents and Adults in Yangon, Myanmar.

Authors:  Win Thandar Oo; Tin Ohn Myat; Wah Win Htike; James E Ussher; David R Murdoch; Kay Thi Lwin; Min Zaw Oo; Michael J Maze; Hla Hla Win; John A Crump
Journal:  Clin Infect Dis       Date:  2019-03-07       Impact factor: 9.079

8.  A retrospective study of patients with blood culture-confirmed typhoid fever in Fiji during 2014-2015: epidemiology, clinical features, treatment and outcome.

Authors:  Aneley Getahun Strobel; Christopher M Parry; John A Crump; Varanisese Rosa; Adam Jenney; Ravi Naidu; Kim Mulholland; Richard A Strugnell
Journal:  Trans R Soc Trop Med Hyg       Date:  2019-12-01       Impact factor: 2.184

9.  Estimating the incidence of typhoid fever and other febrile illnesses in developing countries.

Authors:  John A Crump; Fouad G Youssef; Stephen P Luby; Momtaz O Wasfy; Josefa M Rangel; Maha Taalat; Said A Oun; Frank J Mahoney
Journal:  Emerg Infect Dis       Date:  2003-05       Impact factor: 6.883

10.  Introductory Article on Global Burden and Epidemiology of Typhoid Fever.

Authors:  Amruta Radhakrishnan; Daina Als; Eric D Mintz; John A Crump; Jefferey Stanaway; Robert F Breiman; Zulfiqar A Bhutta
Journal:  Am J Trop Med Hyg       Date:  2018-07-24       Impact factor: 2.345

View more
  2 in total

Review 1.  Travel vaccines throughout history.

Authors:  Androula Pavli; Helena C Maltezou
Journal:  Travel Med Infect Dis       Date:  2022-02-12       Impact factor: 6.211

2.  Typhoid in Bangladesh: Challenges, efforts, and recommendations.

Authors:  Yumna Salman; Hanzla Asim; Narmeen Hashmi; Zarmina Islam; Mohammad Yasir Essar; Md Ariful Haque
Journal:  Ann Med Surg (Lond)       Date:  2022-07-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.